FAQ on Soligenix Inc.'s Clinical Programs and Alliance Global Partners' Updated Valuation
Summary
Alliance Global Partners maintains a Buy rating for Soligenix Inc. (NASDAQ: SNGX) and increases its price target to $10 per share, citing progress in Soligenix's clinical programs for rare diseases, including HyBryte(TM) for CTCL and SGX945 for Behçet’s disease.
What is Soligenix Inc. focused on?
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, including cutaneous T-cell lymphoma (CTCL) and Behçet’s disease.
Why did Alliance Global Partners increase Soligenix’s price target to $10 per share?
Alliance Global Partners increased Soligenix’s price target based on the increasing valuation of HyBryte(TM) for CTCL treatment and the new estimated valuation for SGX945, a treatment for Behçet’s disease, projecting significant future sales.
What is HyBryte(TM) and what is its significance?
HyBryte(TM) is a novel photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), with its phase 3 FLASH2 trial on track for topline results next year, indicating potential for regulatory approval and commercialization.
How does SGX945 perform in treating Behçet’s disease?
SGX945 has shown compelling data in decreasing oral ulcers in Behçet’s disease, with effects continuing through weeks 5–8 even after dosing stops at the 4th week, suggesting biological efficacy similar or superior to existing treatments like Otezla(R).
When are the topline results for the FLASH2 trial expected?
Topline results for the phase 3 FLASH2 trial of HyBryte in CTCL patients are expected to be announced next year, following its initiation in December 2024.
What are the projected sales for HyBryte(TM) and SGX945?
Alliance Global Partners projects HyBryte(TM) could reach U.S. sales of $75M by 2035 and ROW sales of $50M by 2036, while SGX945 for Behçet’s disease could achieve $50M in sales by 2035.
Where can I view the full report from Alliance Global Partners?
The full report can be viewed at https://ibn.fm/6zX9x.
What is the significance of Soligenix’s RiVax(R) program?
Soligenix’s RiVax(R) program is estimated to secure a U.S. government contract for the Strategic National Stockpile, valued at $25M by 2035, contributing to the company’s overall valuation.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 143778